Moreover, in a mouse model of cancer, we demonstrate that when dosed into an anti-PD-1 mAb refractory tumor model, fusion proteins can engage tumor specific CD8+ cells to provide superior tumor control in a manner which is superior to an antagonist anti-PD-1 mAb monotherapy. The gene discussed is CD8A; the disease is cancer.